Straumann Group (STMN) Q1 2025 earnings summary

Executive summary

• Achieved CHF 681 million in Q1 2025 revenue, with 11% organic growth year-over-year, driven by strong demand across all business segments and regions, especially EMEA and APAC.

• APAC and LATAM showed robust growth, with APAC delivering 23% organic growth and LATAM 18.8%, while North America experienced slower momentum.

• Growth was supported by new product launches, digital solutions, and strategic collaborations, including the IXL implant system, Sirius intraoral scanner, and partnerships with SprintRay and Carestream Dental.

• Innovation and customer-centric initiatives, such as the global rollout of Straumann AXS, iEXCEL, and digital workflow enhancements, contributed significantly.

Financial highlights

• Q1 2025 revenue reached CHF 681 million, up 11% organically year-over-year, with APAC leading at 23% organic growth, LATAM at 18.8%, EMEA at 10%, and NAM at 1.8%.

• Foreign currency impact was muted in Q1, but Swiss franc strength may pose headwinds in coming quarters.

• Dividend increased to CHF 0.95 per share, 12% higher than previous year, reflecting commitment to gradual increases in line with earnings.

Outlook and guidance

• 2025 outlook confirmed: targeting high single-digit organic revenue growth and 30–60 basis points core EBIT margin improvement at constant 2024 currency rates.

• Guidance reflects conservatism due to macroeconomic uncertainties, with potential for revision if conditions remain favorable.

• Ongoing investments in production capacity, digital transformation, and clinician training to support growth.